Lilly reinvests tirzepatide windfall into a generational acquisition and innovation run

juanbenet · x · 2026-11-17

Cremieux argues Lilly is on a generational innovation and acquisition run across every domain, actually reinvesting the massive profits from tirzepatide into owning the future of pharma. Juan Benet calls it long-term rational action from big pharma.

Original post →

More from Venture

Venture channel →